Skip to main navigation Skip to search Skip to main content

Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy

  • Helen Dearden
  • , Lewis Au
  • , Daniel Y. Wang
  • , Lisa Zimmer
  • , Zeynep Eroglu
  • , Jessica L. Smith
  • , Marcello Cuvietto
  • , Chloe Khoo
  • , Victoria Atkinson
  • , Serigne Lo
  • , Georgina V. Long
  • , Shahneen Sandhu
  • , Paolo A. Ascierto
  • , Matteo S. Carlino
  • , Douglas B. Johnson
  • , James Larkin
  • , Alexander M. Menzies
  • The University of Sydney
  • Royal Marsden NHS Foundation Trust
  • Vanderbilt University
  • University of Duisburg-Essen
  • Moffitt Cancer Center
  • IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
  • Peter Maccallum Cancer Centre
  • Greenslopes Private Hospital
  • University of Queensland
  • Royal North Shore Hospital

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

Background: Combination ipilimumab and nivolumab is approved for several malignancies. Toxicity most often occurs 6–10 weeks into treatment. Whether very early toxicity is harder to manage or influences efficacy is unknown. Methods: Consecutive metastatic melanoma patients who developed hyperacute toxicity, defined as Grade 2+ irAE within 21 days of receiving ipilimumab + anti-PD-1 were retrospectively identified from nine centres. Results: A total of 82 patients developed hyperacute toxicity (estimated incidence 9%), at a median 10 days (range 1–21). Toxicities included colitis (N = 23), rash (17), hepatitis (9), endocrine (9), pneumonitis (6) and neurotoxicity (4) and were G2 (38%), G3 (52%), G4 (6%) and G5 (2% myocarditis). Fifty-nine percent required treatment beyond oral steroids, including IV steroids (28%), infliximab and other immunosuppression (30%). A total of 29% patients developed an additional hyperacute toxicity and 26% another toxicity >21 days after treatment commencement but before further immunotherapy. The objective response rate (ORR) was 54%, and after a median 11.6 mo follow-up, median PFS was 7.4 mo. Increasing levels of immunosuppression was associated with a reduced PFS (12-month PFS 62% no immunosuppression versus 49% oral steroids versus 33% IV steroids versus 20% further immunosuppressants, p = 0.006). There was no significant difference in ORR or PFS by duration of immunosuppression. Conclusions: Hyperacute toxicities from combination immunotherapy have a wide spectrum and can be severe. Many patients require significant immunosuppression for prolonged durations and remain at risk of further severe toxicity. Melanoma outcomes in such patients appear similar to those of trial populations, although greater immunosuppression requirements may be associated with inferior outcomes.

Original languageEnglish
Pages (from-to)168-178
Number of pages11
JournalEuropean Journal of Cancer
Volume153
DOIs
Publication statusPublished - Aug 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 Elsevier Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Combination
  • Immunotherapy
  • Ipilimumab
  • Melanoma
  • Nivolumab
  • Pembrolizumab
  • Toxicity

Fingerprint

Dive into the research topics of 'Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy'. Together they form a unique fingerprint.

Cite this